Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy

被引：0
|
作者：
Gillison, Maura L. [1 ]
Blumenschein, George, Jr. [2 ]
Fayette, Jerome [3 ]
Guigay, Joel [4 ]
Colevas, A. Dimitrios [5 ]
Licitra, Lisa [6 ,7 ]
Harrington, Kevin J. [8 ]
Kasper, Stefan [9 ]
Vokes, Everett E. [10 ]
Even, Caroline [11 ]
Worden, Francis [12 ]
Saba, Nabil F. [13 ]
Iglesias Docampo, Lara Carmen [14 ]
Haddad, Robert [15 ]
Rordorf, Tamara [16 ]
Kiyota, Naomi [17 ]
Tahara, Makoto [18 ]
Lynch, Mark [19 ]
Kopit, Justin [19 ]
Ferris, Robert L. [20 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Ctr Leon Berard, Lyon, France
[4] FHU OncoAge, Ctr Antoine Lacassagne, Nice, France
[5] Stanford Univ, Stanford, CA 94305 USA
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Milan, Milan, Italy
[8] Inst Canc Res, Royal Marsden NHS Fdn Trust, London, England
[9] Univ Hosp, West German Canc Ctr, Essen, Germany
[10] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[11] Gustave Roussy, Villejuif, France
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Hosp Univ 12 Octubre, Madrid, Spain
[15] Dana Farber Harvard Canc Ctr, Boston, MA USA
[16] Univ Spital Zurich, Zurich, Switzerland
[17] Kobe Univ Hosp, Kobe, Hyogo, Japan
[18] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Univ Pittsburgh, Med Ctr, Ctr Canc, Pittsburgh, PA USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [31] HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany
    Langer, C.
    von der Heyde, E.
    Hahn, D. A.
    Kubuschok, B.
    Bockmuehl, U.
    Mueller-Huesmann, H.
    Klautke, G.
    von der Gruen, J.
    Beutner, D.
    Buentzel, J.
    Busch, C-J.
    Tamaskovics, B. F.
    Knorrenschild, J. Riera
    Gutsche, K.
    Welslau, M. K.
    Gauler, T. C.
    Waldenberger, D.
    Dietz, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S854 - S854
  • [32] Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience
    Bruixola, G.
    Caballero Daroqui, J.
    Cunquero Tomas, A. J.
    Sandiego, S.
    Garcia Sanchez, J.
    Blasco, S.
    Ochenduszko, S.
    Iranzo, A.
    Lavernia, J.
    Berrocal Jaime, A.
    Pastor Borgonon, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Zenda, Sadamoto
    Onozawa, Yusuke
    Boku, Narikazu
    Fida, Yoshiyuki
    Ebihara, Mitsuru
    Onitsuka, Tetsuro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 477 - 481
  • [34] Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)
    Vermorken, J. B.
    Hitt, R.
    Geoffrois, L.
    Erfan, J.
    Kawecki, A.
    Zabolotnyy, D.
    Schueler, A.
    Knecht, R.
    Benasso, M.
    Kienzer, H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 324 - 324
  • [35] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [36] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [39] Estimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial
    Venkatachalam, M.
    Bobiak, S.
    Shaw, J. W.
    Santi, I.
    Contente, M.
    Korytowsky, B.
    Stenehjem, D. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Cetuximab 1 platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)
    Le Tourneau, C.
    Ghiani, M.
    Cau, M. C.
    Depenni, R.
    Ronzino, G.
    Bonomo, P.
    Montesarchio, V.
    Leo, L.
    Schulten, J.
    Messinger, D.
    Sbrana, A.
    Ghi, M. G.
    ANNALS OF ONCOLOGY, 2018, 29
12345